Roivant Reports Breakthrough Phase 2 Brepocitinib Results in Cutaneous Sarcoidosis; Submits NDA for Dermatomyositis

summarizeSummary

Roivant announced highly positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, paving the way for a Phase 3 study, and submitted an NDA for brepocitinib in dermatomyositis, alongside reporting Q3 financial results with a strong cash position.

check_boxKey Events

• Brepocitinib Phase 2 Breakthrough

  Positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) showed significant improvement (Δ21.6 p<0.0001) and a consistent safety profile, leading to plans for a pivotal Phase 3 study in 2026. This marks the third indication for brepocitinib to enter a pivotal program.

• NDA Submission for Dermatomyositis

  A New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM), advancing another key pipeline asset closer to potential market approval.

• Strong Cash Position

  Roivant reported $4.5 billion in consolidated cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2025, providing a cash runway into profitability.

• Pipeline Advancement

  Multiple other clinical trials, including IMVT-1402 in D2T RA and CLE, and mosliciguat in PH-ILD, are fully enrolled with topline data expected in the second half of calendar year 2026.

auto_awesomeAnalysis

Roivant Sciences announced a significant clinical breakthrough with highly positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), a historically underserved disease. The data demonstrated rapid, deep, and sustained improvements, with 100% response rates on multiple endpoints in the 45 mg arm, leading to plans for a pivotal Phase 3 study in 2026. This marks the third indication for brepocitinib to enter a pivotal program, significantly de-risking and advancing a key pipeline asset. Additionally, the company submitted a New Drug Application (NDA) for brepocitinib in dermatomyositis (DM), further progressing its late-stage pipeline. While the company reported increased losses from continuing operations, its robust cash position of $4.5 billion provides a substantial runway into profitability, supporting ongoing clinical development and mitigating financial concerns. The favorable summary judgment in the Moderna LNP litigation also reduces a potential overhang.